Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua M Cohen

Showing results (31-40 of 79) with videos related to

Pageof 8
Sort By:
Plastic and Reconstructive Surgery|September 8, 2021
Evidence-Based Medicine in Plastic Surgery: From Then to NowRod J Rohrich, Joshua M Cohen, Ira L Savetsky, et al.
Cephalalgia : an International Journal of Headache|May 15, 2021
Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate ResponseLadislav Pazdera, Joshua M Cohen, Xiaoping Ning, et al.
The Journal of Headache and Pain|May 5, 2022
A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United StatesLynda J Krasenbaum, Vasantha L Pedarla, Stephen F Thompson, et al.
Neurology|August 5, 2020
Effect of fremanezumab on quality of life and productivity in patients with chronic migraineRichard B Lipton, Joshua M Cohen, Sanjay K Gandhi, et al.
Headache|August 10, 2021
Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS studyEgilius L H Spierings, Xiaoping Ning, Verena Ramirez Campos, et al.
European Journal of Biochemistry|December 21, 2004
Complex transcriptional and translational regulation of iPLAgamma resulting in multiple gene products containing dual competing sites for mitochondrial or peroxisomal localizationDavid J Mancuso, Christopher M Jenkins, Harold F Sims, et al.
Journal of Neurosurgery. Case Lessons|February 23, 2026
Cranial lateral dermal sinus tract: illustrative caseJoshua M Cohen, Hailey D Reisert, Elizabeth Cohen, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|March 17, 2025
Endoscopic endonasal versus open approach for craniopharyngioma treatment: a systematic review of clinical characteristicsGeena Jung, Joshua M Cohen, David Oriko, et al.
Journal of Managed Care & Specialty Pharmacy|July 18, 2020
Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for MigraineDawn C Buse, Marianna S Yugrakh, Lulu K Lee, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|September 28, 2021
Comment on: Gao B, Lu Q, Wan R, Wang Z, Yang Y, Chen Z, Wang Z. "Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials". Naunyn Schmiedebergs Arch Pharmacol. 2021 Apr;394(4):819-828. Epublished November 2020Steve Barash, Verena Ramirez Campos, Xiaoping Ning, et al.
Pageof 8

Showing results (31-40 of 79) with videos related to

Sort By:
Pageof 8
Plastic and Reconstructive Surgery|September 8, 2021
Evidence-Based Medicine in Plastic Surgery: From Then to NowRod J Rohrich, Joshua M Cohen, Ira L Savetsky, et al.
Cephalalgia : an International Journal of Headache|May 15, 2021
Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate ResponseLadislav Pazdera, Joshua M Cohen, Xiaoping Ning, et al.
The Journal of Headache and Pain|May 5, 2022
A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United StatesLynda J Krasenbaum, Vasantha L Pedarla, Stephen F Thompson, et al.
Neurology|August 5, 2020
Effect of fremanezumab on quality of life and productivity in patients with chronic migraineRichard B Lipton, Joshua M Cohen, Sanjay K Gandhi, et al.
Headache|August 10, 2021
Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS studyEgilius L H Spierings, Xiaoping Ning, Verena Ramirez Campos, et al.
European Journal of Biochemistry|December 21, 2004
Complex transcriptional and translational regulation of iPLAgamma resulting in multiple gene products containing dual competing sites for mitochondrial or peroxisomal localizationDavid J Mancuso, Christopher M Jenkins, Harold F Sims, et al.
Journal of Neurosurgery. Case Lessons|February 23, 2026
Cranial lateral dermal sinus tract: illustrative caseJoshua M Cohen, Hailey D Reisert, Elizabeth Cohen, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|March 17, 2025
Endoscopic endonasal versus open approach for craniopharyngioma treatment: a systematic review of clinical characteristicsGeena Jung, Joshua M Cohen, David Oriko, et al.
Journal of Managed Care & Specialty Pharmacy|July 18, 2020
Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for MigraineDawn C Buse, Marianna S Yugrakh, Lulu K Lee, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|September 28, 2021
Comment on: Gao B, Lu Q, Wan R, Wang Z, Yang Y, Chen Z, Wang Z. "Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials". Naunyn Schmiedebergs Arch Pharmacol. 2021 Apr;394(4):819-828. Epublished November 2020Steve Barash, Verena Ramirez Campos, Xiaoping Ning, et al.
Pageof 8